MedTrace Logo

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

NCT02427165 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2016-09-09

No results posted yet for this study

Summary

The number of people with of asthma and allergy is still increasing and a large number of patients still do not have their asthma well controlled. There is therefore a need for new asthma treatments that work well and have less side effects. The study compares a new experimental drug RPL554 with a marketed asthma drug (salbutamol) and placebo.

Conditions

Interventions

DRUG

RPL554

A dual PDE3 and PDE4 inhibitor

DRUG

Salbutamol

a beta-2 receptor agonist

DRUG

Placebo

RPL554 placebo containing no active ingredients

Sponsors & Collaborators

  • Verona Pharma plc

    lead INDUSTRY

Principal Investigators

  • Lief Bjermer · Skane University Hospital, Sweden

  • Johnston Stewart · Celerion, Northern Ireland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02427165 on ClinicalTrials.gov